HIV integrase inhibitors are an important class of antiretroviral medicines used to manage human immunodeficiency virus infection. HIV depends on several viral enzymes to reproduce inside host cells, including reverse transcriptase, protease, and integrase. The integrase enzyme helps HIV insert its genetic material into the DNA of infected cells, creating a foundation for continued viral replication. Integrase inhibitors target this process and prevent a critical stage of the viral life cycle. Their molecular activity, drug characteristics, and role in combination antiretroviral therapy are important areas of study in HIV treatment and pharmacology.
HIV integrase inhibitors, also called integrase strand transfer inhibitors (INSTIs), work by targeting the viral integrase enzyme. After HIV converts its RNA into DNA, integrase helps incorporate that viral DNA into the DNA of a host CD4 cell. INSTIs interfere with the strand transfer process, preventing successful integration and limiting the virus's ability to continue its replication cycle.
The integrase enzyme performs an essential function after reverse transcription. Viral DNA must be integrated into the host cell's genome for HIV to establish productive infection.
The molecular process involves several stages:
Many INSTIs interact with the integrase active site and metal ions involved in its catalytic activity. This interference prevents the enzyme from carrying out the strand transfer reaction needed for viral DNA integration. Dolutegravir, for example, inhibits integrase by binding to its active site. The molecular interaction helps explain how these medicines interrupt a specific step in HIV replication.
The effectiveness of treatment also depends on the virus's susceptibility to the medicine, the presence of resistance-associated mutations, and whether the treatment regimen is taken as prescribed.
Several medicines belong to the INSTI class. They differ in chemical structure, pharmacokinetic properties, dosing requirements, and resistance profiles. Examples include raltegravir, dolutegravir, bictegravir, elvitegravir, and cabotegravir. These medicines are used in different treatment or prevention settings, depending on the specific product and applicable clinical guidance.
Integrase inhibitors are generally used as part of antiretroviral therapy, which combines medicines that act against HIV at different stages of its life cycle. Treatment selection depends on factors such as previous treatment history, resistance testing, other medicines, and individual clinical considerations.
Important considerations include:
Understanding these mechanisms supports research into HIV drug development and the design of treatment strategies that address viral replication and resistance. Integrase inhibitors represent an important component of modern antiretroviral pharmacology, with their activity centered on preventing the integration of viral DNA into host cell DNA.